Search Results

• • 9 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Select Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.

  1

  Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs.

  Authors:Kostantinos E. Morris, Dominic C. Grimberg, Rajan T. Gupta, Avani A. Pendse, and Judd W. MoulFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20222,866 words Article 1460LProstate-specific antigen (PSA) values above 100 ng/mL often suggest metastatic prostate cancer. We present the case of a patient with a PSA of 110 ng/mL, 4 negative prostate biopsies, and 4 negative prostate MRIs. After...
• Select The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study.

  2

  The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study.

  Authors:Kira MacDougall, Muhammad Rafay Khan Niazi, Jeff Hosry, Sylvester Homsy, and Alexander BershadskiyFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20222,553 words Clinical report 1620LINTRODUCTION: Systemic inflammation has long been associated with poor outcomes in many types of solid tumors. Peripheral blood biomarkers, such as absolute lymphocyte count (ALC) and the ratio of absolute neutrophil...
• Select The Emerging Value of ctDNA in Colon Cancer Adjuvant Therapy Decisions.

  3

  The Emerging Value of ctDNA in Colon Cancer Adjuvant Therapy Decisions.

  Author:Howard S. HochsterFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 2022811 words Article 1420LAll our cells die, and then they release DNA strands into the blood stream, which today we can detect as cell-free DNA (cfDNA). A small proportion of this cfDNA is due to death and turnover of tumor cells. This...
• Select Considerations for Treating Thoracic Malignancies.

  4

  Considerations for Treating Thoracic Malignancies.

  Author:Mike Hennessy, Jr.From:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 2022361 words Brief article 1480LIn this issue of ONCOLOGY[R], contributors focus on the treatment of thoracic malignancies. Original research by Kira MacDougall, MD, of the Department of Hematology & Medical Oncology at the Oklahoma University of...
• Select Treatment Options in Metastatic Castration-Sensitive Prostate Cancer.

  5

  Treatment Options in Metastatic Castration-Sensitive Prostate Cancer.

  Author:Atish D. ChoudhuryFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20221,096 words Article 1330LDuring a Clinical Consult presentation, Atish D. Choudhury, MD, PhD, spoke with CancerNetwork[R] about long-term safety and efficacy data for agents related to metastatic castration-sensitive prostate cancer (mCSPC) as...
• Select Matulonis Provides Overview of Gynecologic Treatment Landscape Advances: "Team science is important for being open-minded [and] thinking outside of the box.".

  6

  Matulonis Provides Overview of Gynecologic Treatment Landscape Advances: "Team science is important for being open-minded [and] thinking outside of the box.".

  From:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20221,172 words Interview 1500LThe landscape of gynecologic oncology continues to evolve quickly, with the FDA approving multiple treatments for ovarian, endometrial, and uterine cancer in the last few years. Moreover, investigators continue to...
• Select Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer.

  7

  Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer.

  Author:Wasif M. SaifFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20222,321 words Article 1560LLEARNING OBJECTIVES Upon successful completion of this activity, you should be better prepared to: * Review study data on the immune-related genes and gene expression associated with pancreatic cancer subtypes *...
• Select The Effect of Prior Cancer on Survival of Patients With Thymoma.

  8

  The Effect of Prior Cancer on Survival of Patients With Thymoma.

  Authors:Shilong Wu, Junhua Fang, Ling Ji, Haipeng Liu, Jiufei Li, Wenfa Jiang, et al.From:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 20222,498 words Article 1470LBACKGROUND: Thymoma is an uncommon intrathoracic malignant tumor and has a long natural history, with overall survival (OS) in these patients lasting decades. It is uncertain whether the survival of a patient with...
• Select EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw.

  9

  EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw.

  Author:Evan B. BrysonFrom:Oncology (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 2022854 words Article 1420LProduct Profile Drug name: amivantamab-vmjw (Rybrevant) Date of approval: May 21, 2021 Initial indication: adult patients with locally or advanced metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20...